Transarterial Therapy for Colorectal Liver Metastases.

作者信息

Bhutiani Neal, Martin Robert C G

机构信息

Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, KY, USA.

Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, KY, USA; Division of Surgical Oncology, Upper Gastrointestinal and Hepato-Pancreatico-Biliary Clinic, 315 East Broadway, #311, Louisville, KY 40202, USA.

出版信息

Surg Clin North Am. 2016 Apr;96(2):369-91. doi: 10.1016/j.suc.2015.12.003.

DOI:10.1016/j.suc.2015.12.003

PMID:27017870

Abstract

Until recently, hepatic arterial therapies (HAT) had been used for colorectal liver metastases after failure of first-, second-, and third-line chemotherapies. HAT has gained greater acceptance in patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. The current data demonstrate that HAT is a safe and effective option for preoperative downsizing, optimizing the time to surgery, limiting non-tumor-bearing liver toxicity, and improving overall survival after surgery in patients with colorectal liver-only metastases. The aim of this review is to present the current data for HAT in liver-only and liver-dominant colorectal liver metastases.

摘要